NASHVILLE, Tenn., Oct. 29,
2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX)
("Cryoport" or the "Company"), a global leader in supply chain
solutions for the life sciences industry, today announced that the
Company will report financial results for the third quarter ended
September 30, 2024 on Thursday, November 7, 2024 after U.S. markets
close.
In addition to the earnings release, a document titled "Cryoport
Third Quarter 2024 in Review", providing a review of Cryoport's
financial and operational performance and a general business
update, will be issued at 4:05 p.m. ET on Thursday, November 7, 2024. The document is
designed to be read in advance of the questions and answers
conference call and will be accessible at
https://ir.cryoportinc.com/news-events/ir-calendar.
Cryoport management will host a conference call the same day at
5:00 p.m. ET. The conference call
will be in the format of a questions and answers session and will
address questions members of the investment community have
regarding the Company's reported results. A slide deck will
accompany the call.
Conference Call Information
Date:
|
Thursday, November 7,
2024
|
Time:
|
5:00 p.m. ET
|
Dial-in
numbers:
|
1-800-717-1738 (U.S.),
1-646-307-1865 (International)
|
Confirmation
code:
|
Request the "Cryoport
Call" or Conference ID: 1171580
|
Live
webcast:
|
'Investor Relations'
section at www.cryoportinc.com or click here.
Please allow 10 minutes
prior to the call to visit this site to download and install any
necessary audio software.
|
The questions and answers call will be recorded and available
approximately three hours after completion of the live event in the
Investor Relations section of the Company's website at
www.cryoportinc.com for a limited time. To access the replay of the
questions and answers click here. A dial-in replay of the call will
also be available to those interested, until November 14, 2024. To access the replay, dial
1-844-512-2921 (United States) or
1-412-317-6671 (International) and enter replay entry code:
1171580#.
About Cryoport, Inc
Cryoport, Inc. (Nasdaq: CYRX), is
a global leader in supply chain solutions for the Life Sciences
with an emphasis on cell & gene therapies. Cryoport enables
manufacturers, contract manufacturers (CDMO's), contract research
organizations (CRO's), developers, and researchers to carry out
their respective business with products and services that are
designed to derisk services and provide certainty. We provide a
broad array of supply chain solutions for the life sciences
industry. Through our platform of critical products and solutions
including advanced temperature-controlled packaging, informatics,
specialized bio-logistics services, bio-storage, bio-services, and
cryogenic systems, we are "Enabling the Future of Medicine™"
worldwide, through our innovative systems, compliant procedures,
and agile approach to superior supply chain management.
Our corporate headquarters, located in Nashville, Tennessee, is complemented by over
50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the
Netherlands, Belgium,
Portugal, Germany, Japan, Australia, India, and China.
For more information, visit www.cryoportinc.com or follow via
LinkedIn at https://www.linkedin.com/company/cryoportinc or
@cryoport on X, formerly known as Twitter at www.x.com/cryoport for
live updates.
Forward-Looking Statements
Statements in this press
release which are not purely historical, including statements
regarding Cryoport's intentions, hopes, beliefs, expectations,
representations, projections, plans or predictions of the future,
are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. It is important to note
that Cryoport's actual results could differ materially from those
in any such forward-looking statements. Factors that could cause
actual results to differ materially include, but are not limited
to, risks and uncertainties associated with the effect of changing
economic and geopolitical conditions, supply chain constraints,
inflationary pressures, the effects of foreign currency
fluctuations, trends in the products markets, variations in
Cryoport's cash flow, market acceptance risks, and technical
development risks. Cryoport's business could be affected by other
factors discussed in Cryoport's SEC reports, including in the "Risk
Factors" section of its most recently filed periodic reports on
Form 10-K and Form 10-Q, as well as in its subsequent filings with
the SEC. The forward-looking statements contained in this press
release speak only as of the date hereof and Cryoport cautions
investors not to place undue reliance on these forward-looking
statements. Except as required by law, Cryoport disclaims any
obligation, and does not undertake to update or revise any
forward-looking statements in this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cryoport-to-report-third-quarter-2024-financial-results-on-november-7-2024-302289830.html
SOURCE Cryoport, Inc.